找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Direct Oral Anticoagulants; From Pharmacology to Riccardo Proietti,Ahmed AlTurki,T. Jared Bunch Book 2021 Springer Nature Switzerland AG 20

[復制鏈接]
樓主: FAD
21#
發(fā)表于 2025-3-25 05:24:40 | 只看該作者
https://doi.org/10.1007/978-981-32-9127-0thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE). In patients with multiple conditions, as in particular NVAF ones or with cancer, the contemporary administration of several drugs can cause relevant drug–
22#
發(fā)表于 2025-3-25 08:35:18 | 只看該作者
The Community Street Soccer Programr Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban). They have largely replaced vitamin K anticoagulants (VKAs) in clinical practice. Their overall safety profile concerning bleeding appears to be at least equivalent, if not superior, to VKAs. However, the lack of a specific reversal agent
23#
發(fā)表于 2025-3-25 12:01:28 | 只看該作者
https://doi.org/10.1007/978-1-4614-5996-5ant agents play a key role in preventing this complication. Through years, several risk stratification algorithms have been investigated, while others are still object of debate. According to current guidelines, CHA2DS2VASc score and HAS-BLED score are the ones suggested for stroke and bleeding risk
24#
發(fā)表于 2025-3-25 16:29:23 | 只看該作者
William J. Moreau,Dustin Nabhanmorrhagic events are increased in patients with kidney disease. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivarox
25#
發(fā)表于 2025-3-25 22:12:35 | 只看該作者
26#
發(fā)表于 2025-3-26 03:46:07 | 只看該作者
Brenden J. Balcik,Aaron J. Monseauovascular (CV) risk, more and more evidences suggest a favorable prognosis in obese subjects with cardiovascular disease (CVD), a phenomenon known as “obesity paradox.” Obesity paradox has been demonstrated in various CVD including atrial fibrillation (AF) and venous thromboembolism (VTE) for which
27#
發(fā)表于 2025-3-26 06:57:18 | 只看該作者
https://doi.org/10.1007/978-3-030-36790-9thromboembolism is a leading cause of mortality, especially in patients undergoing chemotherapy. The anticoagulant strategy to be administered in these cases is particularly difficult to choose due to an altered state of coagulation that makes the balance between hypercoagulation and bleeding risk i
28#
發(fā)表于 2025-3-26 12:02:28 | 只看該作者
29#
發(fā)表于 2025-3-26 14:24:55 | 只看該作者
30#
發(fā)表于 2025-3-26 18:58:51 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2025-10-10 17:11
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
融水| 莎车县| 遂川县| 辉南县| 罗城| 平山县| 苗栗县| 宜章县| 迁西县| 江门市| 丹凤县| 贵港市| 南江县| 若羌县| 湖南省| 沭阳县| 东城区| 乌兰县| 越西县| 资兴市| 石嘴山市| 望城县| 石河子市| 吉首市| 南和县| 益阳市| 平邑县| 清苑县| 芦溪县| 阿拉尔市| 兰西县| 揭阳市| 东乌珠穆沁旗| 吴堡县| 鄂伦春自治旗| 泾阳县| 古浪县| 平乡县| 梁河县| 巴林右旗| 阜新市|